The recommendations come at a time when treatments for chronic lymphocytic leukemia (CLL), such as venetoclax, are making deep remissions and undetectable minimal residual disease (MRD) after a fixed ...
The 1996 National Cancer Institute Working Group (NCI/WG) criteria for CLL 25 were used for evaluating response to F-ara-A therapy. The only exception was the bone marrow biopsy criterion for defining ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback